How many 8-K filings has Diamedica Therapeutics Inc. filed?

Diamedica Therapeutics Inc. (DMAC) has 10 8-K (Current Event Report) filings on record, spanning Apr 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Diamedica Therapeutics Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Diamedica Therapeutics Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Diamedica Therapeutics Inc. (DMAC) — 8-K Filings

All 8-K filings from Diamedica Therapeutics Inc.. Browse 10 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (10)

8-K Filing — Dec 18, 2025
DiaMedica Appoints New Chief Medical Officer — Aug 6, 2025 Risk: medium
DiaMedica Therapeutics Inc. announced on August 4, 2025, the appointment of Dr. Michael R. Rick as Chief Medical Officer. Dr. Rick brings extensive experience i
DiaMedica Therapeutics Files 8-K with Key Agreements — Jul 21, 2025 Risk: medium
On July 21, 2025, DiaMedica Therapeutics Inc. filed an 8-K report detailing several events. These include entry into a material definitive agreement, unregister
DiaMedica Therapeutics Files 8-K — Jul 17, 2025 Risk: low
DiaMedica Therapeutics Inc. filed an 8-K on July 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
DiaMedica Therapeutics Files 8-K — May 15, 2025 Risk: low
DiaMedica Therapeutics Inc. filed an 8-K on May 15, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, fo
DiaMedica Appoints New Directors, Updates Executive Contracts — Mar 6, 2025 Risk: medium
DiaMedica Therapeutics Inc. announced on February 28, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two
8-K Filing — Feb 24, 2025
DiaMedica Therapeutics to be Acquired by Cadence Pharmaceuticals for $150M — Jun 26, 2024 Risk: medium
DiaMedica Therapeutics Inc. announced on June 26, 2024, that it has entered into a definitive agreement to be acquired by Cadence Pharmaceuticals, Inc. The tran
DiaMedica Therapeutics Reports Director Changes and Officer Appointment — May 23, 2024 Risk: low
DiaMedica Therapeutics Inc. filed an 8-K on May 23, 2024, reporting on the departure of a director, the election of a new director, and the appointment of a new
DiaMedica Therapeutics Announces Executive and Board Changes — Apr 10, 2024 Risk: medium
DiaMedica Therapeutics Inc. announced on April 5, 2024, a series of executive and board changes. Dr. Robert L. Bridges has been appointed as the new Chief Medic

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX